Higher Semaglutide Dose (7.2 mg) Safe and More Effective for Weight Loss, Study Finds

A higher weekly dose of semaglutide (7.2 mg) has been found safe and more effective for weight loss in adults with obesity, including those with type 2 diabetes (T2D), according to an international study published in The Lancet Diabetes & Endocrinology. The study analyzed results from two large-scale phase 3 clinical trials and reported significant additional weight reduction using the higher dose compared to the currently approved 2.4 mg dose.

In adults without diabetes, the 7.2 mg dose led to an average weight loss of nearly 19%, exceeding the 16% loss seen with the 2.4 mg dose and 4% with placebo. Almost half of the participants achieved weight loss of 20% or more, with about one-third losing at least 25%. Improvements were also noted in waist circumference, blood pressure, blood sugar, and cholesterol levels, indicating reduced obesity-related health risks.

Among adults with obesity and T2D, those receiving the 7.2 mg dose lost 13% of their body weight on average, compared to 10% with the 2.4 mg dose and 3.9% with placebo. These participants also showed significant reductions in blood glucose and waist size. Both trials confirmed that the higher dose was generally well tolerated and safe.

Common side effects included gastrointestinal symptoms such as nausea and diarrhea, as well as sensory effects like tingling. These side effects were manageable and decreased over time, with no increase in serious adverse events or severe hypoglycemia reported. The researchers highlighted the potential of the higher dose to help more people reach weight loss goals and reduce obesity-related complications worldwide.

While the results are promising, the team emphasized the need for further research to understand long-term benefits and risks of the 7.2 mg semaglutide dose. The findings open new avenues for treating obesity, especially for individuals who have struggled with existing therapies.